Microtubule Disruption Reduces Metastasis More Effectively Than Primary Tumor Growth

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2022 Feb 15

PMID 35164808

Authors

Keyata N Thompson

Julia A Ju

Eleanor C Ory

Stephen J P Pratt

Rachel M Lee

Trevor J Mathias

Katarina T Chang

Cornell J Lee

Olga G Goloubeva

Patrick C Bailey

Kristi R Chakrabarti

Christopher M Jewell

Michele I Vitolo

Stuart S Martin

Affiliations

Soon will be listed here.

Abstract

Clinical cancer imaging focuses on tumor growth rather than metastatic phenotypes. The microtubule-depolymerizing drug, Vinorelbine, reduced the metastatic phenotypes of microtentacles, reattachment and tumor cell clustering more than tumor cell viability. Treating mice with Vinorelbine for only 24 h had no significant effect on primary tumor survival, but median metastatic tumor survival was extended from 8 to 30 weeks. Microtentacle inhibition by Vinorelbine was also detectable within 1 h, using tumor cells isolated from blood samples. As few as 11 tumor cells were sufficient to yield 90% power to detect this 1 h Vinorelbine drug response, demonstrating feasibility with the small number of tumor cells available from patient biopsies. This study establishes a proof-of-concept that targeted microtubule disruption can selectively inhibit metastasis and reveals that existing FDA-approved therapies could have anti-metastatic actions that are currently overlooked when focusing exclusively on tumor growth.

Citing Articles

VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis.

Waddell S, Zhao G, Liu Z, Chen H, Zhang W, Wang Y J Pharmacol Exp Ther. 2025; 392(1):100006.

PMID: 39893008 PMC: 11808928. DOI: 10.1124/jpet.124.002298.

Tubulin-Based Microtentacles Aid in Heterotypic Clustering of Neutrophil-Differentiated HL-60 Cells and Breast Tumor Cells.

Ju J, Thompson K, Annis D, Mull M, Gilchrist D, Moriarty A Adv Sci (Weinh). 2024; 12(6):e2409260.

PMID: 39696759 PMC: 11809343. DOI: 10.1002/advs.202409260.

Molecular Profiling of Circulating Tumour Cells and Circulating Tumour DNA: Complementary Insights from a Single Blood Sample Utilising the Parsortix System.

Wishart G, Templeman A, Hendry F, Miller K, Pailhes-Jimenez A Curr Issues Mol Biol. 2024; 46(1):773-787.

PMID: 38248352 PMC: 10814787. DOI: 10.3390/cimb46010050.

Ectopic Expression of a Truncated Isoform of Hair Keratin 81 in Breast Cancer Alters Biophysical Characteristics to Promote Metastatic Propensity.

Kang D, Moriarty A, Wang Y, Thomas A, Hao J, Unger B Adv Sci (Weinh). 2023; 11(5):e2300509.

PMID: 37949677 PMC: 10837353. DOI: 10.1002/advs.202300509.

Isolation and Anticancer Progression Evaluation of the Chemical Constituents from Tutcher.

Zhao L, Xie W, Du Y, Xia Y, Liu K, Ku C Molecules. 2023; 28(16).

PMID: 37630417 PMC: 10457964. DOI: 10.3390/molecules28166165.

References

Shriver M, Stroka K, Vitolo M, Martin S, Huso D, Konstantopoulos K . Loss of giant obscurins from breast epithelium promotes epithelial-to-mesenchymal transition, tumorigenicity and metastasis. Oncogene. 2014; 34(32):4248-59. PMC: 4426246. DOI: 10.1038/onc.2014.358. View

Marino N, Woditschka S, Reed L, Nakayama J, Mayer M, Wetzel M . Breast cancer metastasis: issues for the personalization of its prevention and treatment. Am J Pathol. 2013; 183(4):1084-1095. PMC: 3791679. DOI: 10.1016/j.ajpath.2013.06.012. View

Wahby S, Fashoyin-Aje L, Osgood C, Cheng J, Fiero M, Zhang L . FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer. Clin Cancer Res. 2020; 27(7):1850-1854. DOI: 10.1158/1078-0432.CCR-20-3119. View

Bourgeois H, Vermorken J, Dark G, Jones A, Fumoleau P, Stupp R . Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. Cancer Chemother Pharmacol. 2007; 60(3):407-13. DOI: 10.1007/s00280-007-0510-z. View

Lehmann B, Jovanovic B, Chen X, Estrada M, Johnson K, Shyr Y . Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11(6):e0157368. PMC: 4911051. DOI: 10.1371/journal.pone.0157368. View

Matrone M, Whipple R, Thompson K, Cho E, Vitolo M, Balzer E . Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells. Oncogene. 2010; 29(22):3217-27. PMC: 3132415. DOI: 10.1038/onc.2010.68. View

Boggs A, Vitolo M, Whipple R, Charpentier M, Goloubeva O, Ioffe O . α-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. Cancer Res. 2014; 75(1):203-15. PMC: 4350791. DOI: 10.1158/0008-5472.CAN-13-3563. View

Nair A, Morsy M, Jacob S . Dose translation between laboratory animals and human in preclinical and clinical phases of drug development. Drug Dev Res. 2018; 79(8):373-382. DOI: 10.1002/ddr.21461. View

Camara O, Kavallaris A, Noschel H, Rengsberger M, Jorke C, Pachmann K . Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells. World J Surg Oncol. 2006; 4:67. PMC: 1599731. DOI: 10.1186/1477-7819-4-67. View

10.

Whipple R, Balzer E, Cho E, Matrone M, Yoon J, Martin S . Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells. Cancer Res. 2008; 68(14):5678-88. PMC: 2859318. DOI: 10.1158/0008-5472.CAN-07-6589. View

11.

Hotta T, Haynes S, Blasius T, Gebbie M, Eberhardt E, Sept D . Parthenolide Destabilizes Microtubules by Covalently Modifying Tubulin. Curr Biol. 2021; 31(4):900-907.e6. PMC: 7931505. DOI: 10.1016/j.cub.2020.11.055. View

12.

Hvichia G, Parveen Z, Wagner C, Janning M, Quidde J, Stein A . A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells. Int J Cancer. 2016; 138(12):2894-904. PMC: 5069649. DOI: 10.1002/ijc.30007. View

13.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

14.

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

15.

Webster M, Muller W . Mammary tumorigenesis and metastasis in transgenic mice. Semin Cancer Biol. 1994; 5(1):69-76. View

16.

Pastoriza J, Karagiannis G, Lin J, Lanjewar S, Entenberg D, Condeelis J . Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer. Clin Exp Metastasis. 2018; 35(7):613-623. PMC: 6202136. DOI: 10.1007/s10585-018-9932-8. View

17.

Whipple R, Vitolo M, Boggs A, Charpentier M, Thompson K, Martin S . Parthenolide and costunolide reduce microtentacles and tumor cell attachment by selectively targeting detyrosinated tubulin independent from NF-κB inhibition. Breast Cancer Res. 2013; 15(5):R83. PMC: 3979133. DOI: 10.1186/bcr3477. View

18.

Seraj M, Samant R, Verderame M, Welch D . Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res. 2000; 60(11):2764-9. View

19.

Chakrabarti K, Andorko J, Whipple R, Zhang P, Sooklal E, Martin S . Lipid tethering of breast tumor cells enables real-time imaging of free-floating cell dynamics and drug response. Oncotarget. 2016; 7(9):10486-97. PMC: 4891134. DOI: 10.18632/oncotarget.7251. View

20.

Karagiannis G, Pastoriza J, Wang Y, Harney A, Entenberg D, Pignatelli J . Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Sci Transl Med. 2017; 9(397). PMC: 5592784. DOI: 10.1126/scitranslmed.aan0026. View